Virtual screening, optimization, and identification of a novel specific PTP-MEG2 Inhibitor with potential therapy for T2DM.

Wang, Meiyan; Li, Xiaobo; Dong, Lei; Chen, Xiubo; Xu, Weiren; Wang, Runling

Wang, Meiyan; Li, Xiaobo; Dong, Lei; Chen, Xiubo; Xu, Weiren; Wang, Runling.

Afiliación

Wang M; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Li X; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Dong L; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Chen X; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Xu W; Tianjin Medical University Eye Hospital, Tianjin, China.
Wang R; Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, China.

Oncotarget ; 7(32): 50828-50834, 2016 Aug 09.

Article en En | MEDLINE | ID: mdl-27384997

Asunto(s)

Diabetes Mellitus Tipo 2; Inhibidores Enzimáticos/química; Megacariocitos/enzimología; Proteínas Tirosina Fosfatasas/antagonistas & inhibidores; Evaluación Preclínica de Medicamentos/métodos; Inhibidores Enzimáticos/farmacología; Humanos

Palabras clave

Gerotarget; PTP-MEG2 inhibitor; core hopping; diabetes; molecular dynamics simulation; selectivity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Megacariocitos / Proteínas Tirosina Fosfatasas / Diabetes Mellitus Tipo 2 / Inhibidores Enzimáticos Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google